Patent 7122530 was granted and assigned to Genzyme on October, 2006 by the United States Patent and Trademark Office.
The invention provides 24-hydroxyvitamin D compounds and methods for their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders.